Exelixis, Inc. (EXEL)

Exelixis, Inc. (EXEL) is a healthcare company (biotechnology) based in the United States. The share price is $68.05, up 1.42% on the day, which values the company at $16.6B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.

Key facts

Share price
$68.05+1.42% today
Market value
$16.6B
P/E ratio
20.4×last 12 months
Forward P/E
15.9×
Funk Score
78/100
Against its own history
Well above its usual priceusual price $48.62
200-week average
$33.97100% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Exelixis, Inc. in more detail

EXEL trades at 20.4× its last twelve months' earnings, 15.9× next year's expected earnings, 6.7× sales. Measured against its own history, the price is 40% above what its usual multiples would imply ($48.62) — well above its usual price. It sits 100% above its 200-week average of $33.97.

Over the last five fiscal years Exelixis, Inc. has compounded revenue 19.1% a year, earnings per share 22.2% a year, free cash flow 10.4% a year. Its Funk Score is 78 out of 100 (financial strength 9.6, profitability 9.8, growth 8.4, value 3.6, each out of 10).

In its favour: Strong Piotroski score; Share count keeps falling.

5 of the superinvestors tracked here hold EXEL, including Andrew Spokes (4.5% of the portfolio), Jim Simons (1938–2024) (1.0% of the portfolio), Josef Lakonishok (0.9% of the portfolio).

Superinvestors holding EXEL

5 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:EXEL vs CRL (Exelixis, Inc. vs Charles River Laboratories International)EXEL vs NBIX (Exelixis, Inc. vs Neurocrine Biosciences)EXEL vs RVTY (Exelixis, Inc. vs Revvity)EXEL vs ASND (Exelixis, Inc. vs Ascendis Pharma)EXEL vs MEDP (Exelixis, Inc. vs Medpace Holdings)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Exelixis, Inc. (EXEL): questions and answers

What is EXEL's P/E ratio?

Exelixis, Inc. trades at 20.4× its last twelve months' earnings and 15.9× next year's expected earnings. At its fiscal year-ends over the past 10 years the P/E ranged from 8.2× to 62.0×, with a median of 22.2×.

What is EXEL's PEG ratio?

Exelixis, Inc.'s PEG ratio is 2.56 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Exelixis, Inc.'s market cap?

Exelixis, Inc. is valued at $16.6B at a share price of $68.05.

Is EXEL overvalued or undervalued?

Against its own history, EXEL is well above its usual price: the price is 40% above the $48.62 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is EXEL above its 200-week moving average?

Yes. EXEL is 100.3% above its 200-week average of $33.97. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Exelixis, Inc. growing?

Over the last five fiscal years Exelixis, Inc.'s revenue grew 19.1% a year and its earnings per share 22.2% a year; over ten years revenue grew 51.2% a year.

Cite this page

Funkfolio, “Exelixis, Inc. (EXEL) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/EXEL

Underlying data: Yahoo Finance; company filings with the SEC.